| answer text |
<p>In June 2013 the National Institute for Health and Care Excellence (NICE) issued
an updated clinical guideline on familial breast cancer which includes recommendations
on the use of tamoxifen and raloxifene outside their licensed indications for the
prevention of cancer in specific groups of women at high and moderate risk of breast
cancer.</p><p> </p><p> </p><p> </p><p>NICE’s clinical guidelines represent best practice
and we expect commissioners to take their recommendations into account when designing
services and making commissioning decisions for their healthcare population.</p><p>
</p><p><strong> </strong></p><p> </p><p>Our assessment is that, as NICE has already
provided guidance on the use of tamoxifen and raloxifene, there would be little value
in NICE separately appraising these drugs for the prevention of breast cancer and
we have had no discussions with NICE on this issue.</p><p> </p><p> </p><p> </p><p>
</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p>
|
|
